Published in Nucleic Acids Res on September 08, 2014
TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB. Prostate (2016) 0.78
Whole-exome sequencing of Finnish hereditary breast cancer families. Eur J Hum Genet (2016) 0.75
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant. PLoS One (2017) 0.75
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells. Oncogenesis (2017) 0.75
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
Widespread transcription at neuronal activity-regulated enhancers. Nature (2010) 16.52
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
AP-1 in cell proliferation and survival. Oncogene (2001) 6.07
A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol (2010) 6.01
Progression through the RNA polymerase II CTD cycle. Mol Cell (2009) 5.62
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell (2005) 5.38
MAPK signal specificity: the right place at the right time. Trends Biochem Sci (2006) 3.96
Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene (2001) 3.83
Tails of intrigue: phosphorylation of RNA polymerase II mediates histone methylation. Cell (2003) 3.82
Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol (2010) 3.77
The human Mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci (2010) 3.38
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res (2007) 3.21
Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J Biol Chem (2005) 2.68
The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer (2005) 2.63
Function and regulation of the Mediator complex. Curr Opin Genet Dev (2011) 2.51
The role of enhancers as centres for general transcription factor recruitment. Trends Biochem Sci (2005) 2.14
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
Transcription factors control invasion: AP-1 the first among equals. Oncogene (2006) 1.78
Modifications of RNA polymerase II are pivotal in regulating gene expression states. EMBO Rep (2009) 1.78
Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer (2010) 1.76
FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene (2005) 1.74
The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett (2009) 1.68
Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochim Biophys Acta (2006) 1.61
A facilitated tracking and transcription mechanism of long-range enhancer function. Nucleic Acids Res (2007) 1.60
Histone H3 acetylated at lysine 9 in promoter is associated with low nucleosome density in the vicinity of transcription start site in human cell. Chromosome Res (2006) 1.50
Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle (2007) 1.42
Fra-1 a target for cancer prevention or intervention. Gene (2006) 1.35
Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol Cell Biol (2002) 1.26
c-fos proto-oncogene regulation and function. Crit Rev Oncol Hematol (1994) 1.25
Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells. EMBO J (2009) 1.23
The HS2 enhancer of the beta-globin locus control region initiates synthesis of non-coding, polyadenylated RNAs independent of a cis-linked globin promoter. J Mol Biol (2005) 1.23
The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene (2009) 1.17
Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol (2007) 1.16
CYCLINg through transcription: posttranslational modifications of P-TEFb regulate transcription elongation. Cell Cycle (2010) 1.16
The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat (2004) 1.14
An upstream enhancer and a negative element in the 5' flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res (1988) 1.13
In vivo live imaging of RNA polymerase II transcription factories in primary cells. Genes Dev (2013) 1.12
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer (2013) 1.12
Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2. Gene (1997) 1.07
Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene (2011) 1.05
Fra-1 regulates vimentin during Ha-RAS-induced epithelial mesenchymal transition in human colon carcinoma cells. Int J Cancer (2008) 1.03
FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer (2007) 1.03
Binding site specificity and factor redundancy in activator protein-1-driven human papillomavirus chromatin-dependent transcription. J Biol Chem (2011) 1.02
Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J (2007) 1.00
A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. J Cell Physiol (2008) 0.98
The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene (2012) 0.94
Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility. Oncogene (2003) 0.94
Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J Biol Chem (2001) 0.93
Mediator MED23 regulates basal transcription in vivo via an interaction with P-TEFb. Transcription (2013) 0.92
Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking. Mol Cell Biol (2008) 0.92
Synergistic activation of human involucrin gene expression by Fra-1 and p300--evidence for the presence of a multiprotein complex. J Invest Dermatol (2007) 0.91
A transcription-dependent micrococcal nuclease-resistant fragment of the urokinase-type plasminogen activator promoter interacts with the enhancer. J Biol Chem (2007) 0.89
Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signaling pathway. J Biol Chem (1997) 0.89
Protease nexin-1 expression is altered in human breast cancer. Cancer Cell Int (2006) 0.87
Role of distinct mitogen-activated protein kinase pathways and cooperation between Ets-2, ATF-2, and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate. Mol Cell Biol (1999) 0.86
An NF-kappaB-dependent role for JunB in the induction of proinflammatory cytokines in LPS-activated bone marrow-derived dendritic cells. PLoS One (2010) 0.84
Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation. Int J Cancer (1999) 0.81
[UPA/PAI-1: a tool for breast cancer treatment individualization. Biology, clinical implications and quantification assays]. Bull Cancer (2010) 0.78
Oct-1 specifically binds the UEF4 site of the human AP1-regulated urokinase enhancer. Eur J Biochem (2000) 0.78